Alpha Spread
Search stocks here...
A
52Q
PHLL
Sign Up Log in
Dashboard AI Assistant Stock Comparison Intrinsic Value Calculator DCF Value Calculator Stock Screener
Pricing Market News Investing Ideas
Settings
Alpha Spread
Dashboard Tools Market News Investing Ideas Pricing About Us
Sign Up
Log in
Alpha Spread
Dashboard Tools Market News Investing Ideas Pricing About Us
Sign Up
Log in
A

Aegirbio AB
F:52Q

Watchlist Manager
Aegirbio AB
F:52Q
Watchlist
Summary
DCF Valuation
Relative Valuation
Wall St Estimates
Profitability
Solvency
Financials
Dividends
Investor Relations
Discount Rate
Price: 0.0002 EUR
Market Cap: 7.2k EUR
Have any thoughts about
Aegirbio AB?
Write Note
Write Note Create Alert Ask AI
Add Note Why Create Notes?
Capture your thoughts
Note Buy Sell Hold Pass
US
Johnson & Johnson
NYSE:JNJ
Pharmaceuticals
US
Berkshire Hathaway Inc
NYSE:BRK.A
Financial Services
US
Bank of America Corp
NYSE:BAC
Banking
US
Mastercard Inc
NYSE:MA
Technology
US
UnitedHealth Group Inc
NYSE:UNH
Health Care
US
Exxon Mobil Corp
NYSE:XOM
Energy
US
Pfizer Inc
NYSE:PFE
Pharmaceuticals
US
Palantir Technologies Inc
NYSE:PLTR
Technology
US
Nike Inc
NYSE:NKE
Textiles, Apparel & Luxury Goods
US
Visa Inc
NYSE:V
Technology
CN
Alibaba Group Holding Ltd
NYSE:BABA
Retail
US
JPMorgan Chase & Co
NYSE:JPM
Banking
US
Coca-Cola Co
NYSE:KO
Beverages
US
Walmart Inc
NYSE:WMT
Retail
US
Verizon Communications Inc
NYSE:VZ
Telecommunication
US
Chevron Corp
NYSE:CVX
Energy


Add Price Alert
Price Target:
Last Price: 0.0002 EUR

We'll email you a reminder when the closing price reaches USD.

If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.

Peter Lynch
Track and Analyze Performance

Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.

Continuous Learning and Adaptation

Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.

Boost Decision Confidence

With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.

Why create notes?
Close
Back
Delete Note

Do you really want to delete this note?
This action cannot be undone.

Delete
Cancel
52Q Alert
Aegirbio AB
0.0002
0.0000 (0%)
52 Week Range
0.0001
0.0229
Price Target

We'll email you a reminder when the closing price reaches EUR.

Save Alert

Choose the stock you wish to monitor with a price alert.

Johnson & Johnson
NYSE:JNJ
US
Berkshire Hathaway Inc
NYSE:BRK.A
US
Bank of America Corp
NYSE:BAC
US
Mastercard Inc
NYSE:MA
US
UnitedHealth Group Inc
NYSE:UNH
US
Exxon Mobil Corp
NYSE:XOM
US
Pfizer Inc
NYSE:PFE
US
Palantir Technologies Inc
NYSE:PLTR
US
Nike Inc
NYSE:NKE
US
Visa Inc
NYSE:V
US
Alibaba Group Holding Ltd
NYSE:BABA
CN
JPMorgan Chase & Co
NYSE:JPM
US
Coca-Cola Co
NYSE:KO
US
Walmart Inc
NYSE:WMT
US
Verizon Communications Inc
NYSE:VZ
US
Chevron Corp
NYSE:CVX
US
Delete Alert

This alert will be permanently deleted.

Delete
Cancel
Relative ValueValuation MultiplesMultiples Across CompetitorsSee Also
Section:
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

There is not enough data to reliably calculate the relative value of 52Q.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Valuation FAQ:
What is Relative Valuation?
How is Relative Value calculated?
52Q Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

191.7
P/S
P/S
Price to Sales
191.7
vs History
38
vs Industry
10
Median 3Y
191.7
Median 5Y
191.7
Industry
7.5
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-0.1
Median 5Y
-0.4
Industry
25
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-0.5
Median 5Y
-0.9
Industry
20.2
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-0.6
Median 5Y
-2
Industry
22.5
More Details
Negative
P/B
P/B
Price to Book Value
N/A
vs History
vs Industry
Median 3Y
-0.7
Median 5Y
0.7
Industry
3.2
More Details
1 158.2
EV/S
EV/S
Enterprise Value to Sales
1 158.2
vs History
20
vs Industry
3
Median 3Y
1 158.2
Median 5Y
440.8
Industry
8.1
More Details
325.7
EV/GP
EV/GP
Enterprise Value to Gross Profit
325.7
vs History
26
vs Industry
4
Median 3Y
325.7
Median 5Y
197.5
Industry
10.1
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
Median 3Y
-0.8
Median 5Y
-1
Industry
6.1
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-0.8
Median 5Y
-1
Industry
6.5
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
Median 3Y
-1.2
Median 5Y
-1.3
Industry
7.1
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-0.9
Median 5Y
-1
Industry
5.7
More Details
0.8
EV/IC
EV/IC
Enterprise Value to IC
0.8
vs History
52
vs Industry
60
Median 3Y
0.8
Median 5Y
0.8
Industry
5.5
More Details

Multiples Across Competitors

52Q Competitors Multiples
Aegirbio AB Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries United States of America United Kingdom Canada New Zealand Germany Bermuda Ireland Luxembourg Austria Italy France Belgium Netherlands Portugal Switzerland Spain Lithuania Estonia Latvia Finland Iceland Sweden Norway Denmark Israel Hong Kong Korea Poland Hungary Philippines Singapore India Japan Pakistan Australia Chile Saudi Arabia Thailand China Indonesia Greece South Africa Vietnam Malaysia Brazil Argentina Mexico Croatia Turkey Taiwan Peru Russia Cyprus Cayman Islands Papua New Guinea Mongolia Guernsey British Virgin Islands Panama Puerto Rico Monaco Colombia Uruguay United Arab Emirates Macao Egypt Bahamas Jersey Anguilla Nicaragua Isle of Man Mauritius Guam Venezuela Czech Republic Malta Liechtenstein Georgia Cambodia Azerbaijan Ukraine French Guiana Martinique Costa Rica Gibraltar Morocco Virgin Islands (U.S.) Faroe Islands Nigeria Bulgaria Slovenia Slovakia Romania Kazakhstan Jordan Kenya Zimbabwe Malawi
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
SE
A
Aegirbio AB
F:52Q
6.9m EUR 191.7 -0.1 -0.8 -0.8
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 409 050.7 -163 541.1 -198 591.1 -196 324.9
US
Abbvie Inc
NYSE:ABBV
385.2B USD 6.6 103.5 16.9 24.5
US
Amgen Inc
NASDAQ:AMGN
160.6B USD 4.6 24.3 18.9 18.9
US
Gilead Sciences Inc
NASDAQ:GILD
148.8B USD 5.1 18.3 12.3 12.3
US
E
Epizyme Inc
F:EPE
94.1B EUR 2 047.4 -522.4 -568.9 -553.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
109.1B USD 9.6 30 22.2 23.2
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
68.6B USD 4.8 15 14.1 16
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
59.7B USD 24.3 -187.2 -468.1 -321.3
AU
CSL Ltd
ASX:CSL
84.9B AUD 3.6 18.5 12.5 15.6
NL
argenx SE
XBRU:ARGX
43.4B EUR 13.9 32.7 56.1 57.7
P/S Multiple
Revenue Growth P/S to Growth
SE
A
Aegirbio AB
F:52Q
Average P/S: 3 128 305.7
191.7
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
34 409 050.7
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.6
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.6
4%
1.1
US
Gilead Sciences Inc
NASDAQ:GILD
5.1
4%
1.3
US
E
Epizyme Inc
F:EPE
2 047.4
N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.6
10%
1
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.8
5%
1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
24.3
42%
0.6
AU
CSL Ltd
ASX:CSL
3.6
6%
0.6
NL
argenx SE
XBRU:ARGX
13.9
44%
0.3
P/E Multiple
Earnings Growth PEG
SE
A
Aegirbio AB
F:52Q
Average P/E: 34.6
Negative Multiple: -0.1 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -163 541.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
103.5
89%
1.2
US
Amgen Inc
NASDAQ:AMGN
24.3
44%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
18.3
191%
0.1
US
E
Epizyme Inc
F:EPE
Negative Multiple: -522.4 N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
30
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15
7%
2.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -187.2 N/A N/A
AU
CSL Ltd
ASX:CSL
18.5
14%
1.3
NL
argenx SE
XBRU:ARGX
32.7
34%
1
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
SE
A
Aegirbio AB
F:52Q
Average EV/EBITDA: 21.9
Negative Multiple: -0.8 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -198 591.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.9
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.9
10%
1.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.3
7%
1.8
US
E
Epizyme Inc
F:EPE
Negative Multiple: -568.9 N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.2
16%
1.4
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
14.1
9%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -468.1 N/A N/A
AU
CSL Ltd
ASX:CSL
12.5
11%
1.1
NL
argenx SE
XBRU:ARGX
56.1
769%
0.1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
SE
A
Aegirbio AB
F:52Q
Average EV/EBIT: 24
Negative Multiple: -0.8 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -196 324.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
24.5
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.9
19%
1
US
Gilead Sciences Inc
NASDAQ:GILD
12.3
13%
0.9
US
E
Epizyme Inc
F:EPE
Negative Multiple: -553.7 N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.2
17%
1.4
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16
12%
1.3
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -321.3 N/A N/A
AU
CSL Ltd
ASX:CSL
15.6
14%
1.1
NL
argenx SE
XBRU:ARGX
57.7
N/A N/A

See Also

Summary
52Q intrinsic value, competitors valuation, and company profile.
DCF Valuation
52Q stock valuation using Discount Cash Flow valuation method.
Relative Valuation
52Q stock valuation using valuation multiples.
Wall Street Estimates
52Q price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
52Q stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 293,800+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.

What is relative valuation?

Relative valuation is used to value companies by comparing them to other businesses based on certain metrics such as EV/Revenue, EV/EBITDA, and P/E ratios.

Relative valuation is one of two methods of placing a monetary value on a company; the other is Discounted Cash Flow valuation method. We use a combination of these two methods to calculate the Intrinsic Value of stock as accurately as possible.

Read more
Close
How is Relative Value calculated?

Our algorithm takes into account all the information about the company's valuation multiples (their historical values, how competitors are priced, and much more) and consolidates it into one single number - relative value.

Read more
Close
Alpha Spread
Recent chats
No chats
Dashboard Pricing
Sign Up
How can I help you with
Aegirbio AB
Build a valuation summary for 52Q
Create a one-page visual summary for Aegirbio AB (52Q): - Current price vs intrinsic value range. - Key valuation multiples. - 1-3 bullet takeaways in plain English explaining how expensive or cheap the stock looks and what could close the valuation gap.
A
52Q
Estimate the DCF value of 52Q
Calculate the DCF value of Aegirbio AB using its latest financial data. Add a table showing the DCF model. Include a separate “Model Assumptions” block listing the key inputs used in the DCF.
A
52Q
Why is 52Q valued this way?
Explain in plain English what drives Alpha Spread’s intrinsic value estimate for Aegirbio AB. List the main assumptions (revenue growth, profit margin, discount rate, etc) and describe how each affects intrinsic value. Show a small table with each assumption and its contribution to valuation. End with 3 simple takeaways: what drives the valuation up, what pressures it down, and what to watch going forward.
A
52Q
Build a valuation summary for 52Q
Create a one-page visual summary for Aegirbio AB (52Q): - Current price vs intrinsic value range. - Key valuation multiples. - 1-3 bullet takeaways in plain English explaining how expensive or cheap the stock looks and what could close the valuation gap.
A
52Q
Estimate the DCF value of 52Q
Calculate the DCF value of Aegirbio AB using its latest financial data. Add a table showing the DCF model. Include a separate “Model Assumptions” block listing the key inputs used in the DCF.
A
52Q
Why is 52Q valued this way?
Explain in plain English what drives Alpha Spread’s intrinsic value estimate for Aegirbio AB. List the main assumptions (revenue growth, profit margin, discount rate, etc) and describe how each affects intrinsic value. Show a small table with each assumption and its contribution to valuation. End with 3 simple takeaways: what drives the valuation up, what pressures it down, and what to watch going forward.
A
52Q
Refresh
GPT-5 Mini
GPT-5 GPT-5 Mini

The AI Assistant may make mistakes. Consider checking important information. Learn more.

Alpha Spread
Become a more intelligent investor
Sign up with Google
OR
Sign up with email
Already have an account? Sign in
By using Alpha Spread you are agreeing to our
Terms of Service and Privacy Policy.
Sign In
Become a more intelligent investor
Sign in with Google
OR
Sign in with email
Not a member? Sign Up
By using Alpha Spread you are agreeing to our
Terms of Service and Privacy Policy.
Recently Viewed Most Popular Most Undervalued Wide Economic Moat High Profitability High Solvency
A
Aegirbio AB
F:52Q
0.0002 EUR
Petershill Partners PLC
LSE:PHLL
312.5 GBX
0.32%

Companies most frequently analyzed and tracked by Alpha Spread users.

Johnson & Johnson
NYSE:JNJ
188.87 USD
-0.1%
Berkshire Hathaway Inc
NYSE:BRK.A
715 740 USD
-0.3%
Bank of America Corp
NYSE:BAC
53.45 USD
0.79%
Mastercard Inc
NYSE:MA
551.99 USD
-0.31%
UnitedHealth Group Inc
NYSE:UNH
341.56 USD
-0.93%
Exxon Mobil Corp
NYSE:XOM
114.36 USD
-0.29%
View Most Popular Stocks Full List

Every business has a fair value, its true price. Where market price tells you the price other people are willing to pay, fair value shows the value of a stock based on an analysis of the company’s actual financials (such as cash balance, revenue, operating margin, etc).

Franklin Covey Co
NYSE:FC
16.96 USD
0.06%
Mohawk Industries Inc
NYSE:MHK
113.64 USD
-1.69%
Ardmore Shipping Corp
NYSE:ASC
12.59 USD
1.04%
ASGN Inc
NYSE:ASGN
44.76 USD
2.12%
Skyworks Solutions Inc
NASDAQ:SWKS
77.72 USD
-1.82%
Weatherford International PLC
NASDAQ:WFRD
73.69 USD
1.57%
View Most Undervalued Stocks Full List

Economic Moat is a concept popularized by Warren Buffett to describe a company's durable competitive advantage. It represents the 'moat' that protects a company from competitors and helps it sustain profitability over the long term.

Johnson & Johnson
NYSE:JNJ
188.87 USD
-0.1%
Bank of America Corp
NYSE:BAC
53.45 USD
0.79%
Mastercard Inc
NYSE:MA
551.99 USD
-0.31%
Salesforce Inc
NYSE:CRM
260.41 USD
1.47%
Abbvie Inc
NYSE:ABBV
218.04 USD
-4.45%
Home Depot Inc
NYSE:HD
379.59 USD
0.01%
View Wide Economic Moat Stocks Full List

Companies demonstrating exceptional profitability and efficient operations.

Monolithic Power Systems Inc
NASDAQ:MPWR
1 005 USD
-7.59%
Applovin Corp
NASDAQ:APP
637.33 USD
2.69%
NVIDIA Corp
NASDAQ:NVDA
202.49 USD
-0.2%
Cal-Maine Foods Inc
NASDAQ:CALM
87.8 USD
1.07%
Pro Medicus Ltd
ASX:PME
261.6 AUD
0.28%
P
Plover Bay Technologies Ltd
HKEX:1523
6.38 HKD
-0.62%
View High Profitability Stocks Full List

Companies with the lowest probability of bankruptcy.

Salesforce Inc
NYSE:CRM
260.41 USD
1.47%
ServiceNow Inc
NYSE:NOW
919.28 USD
-1.65%
Spotify Technology SA
NYSE:SPOT
655.32 USD
-0.21%
Applied Materials Inc
NASDAQ:AMAT
233.1 USD
0.24%
NVIDIA Corp
NASDAQ:NVDA
202.49 USD
-0.2%
NetEase Inc
NASDAQ:NTES
140.1 USD
0.76%
View High Solvency Stocks Full List
AI Assistant
Get AI-powered insights for any company or topic.
Open AI Assistant
Last conversations
Other Tools
Stock Comparison
Smarter decisions through side-by-side analysis
Intrinsic Value Calculator
Discover the true worth of your stocks
DCF Value Calculator
Harness the power of DCF
Stock Screener
Discover stocks

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett
The AI Assistant may be inaccurate

The AI Assistant may sometimes provide inaccurate information.

This is not financial advice

Make your own investment decisions or consult a licensed financial advisor.

Close
Create Your Free Account
Already have an account? Sign in
Gain access to the world’s leading value investing platform
Gain access to the world’s leading value investing platform

By using Alpha Spread you are agreeing to our Terms of Service and Privacy Policy.

Sign up with Google
OR
Create Free Account

By using Alpha Spread you are agreeing to our Terms of Service and Privacy Policy.